NASDAQ · PGENHealthcarePharmaceuticals

Precigen financials

$8.05+3.07%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$9.7M$3.9M$6.2M$26.9M$14.3M$32.0M
Gross profit$4.9M-$342.0K$106.0K$20.6M$8.5M$26.6M
Gross margin50.2%−8.7%1.7%76.4%59.7%83.2%
Operating income-$110.5M-$135.0M-$99.8M-$75.7M-$91.9M-$86.3M
Net income-$429.6M-$126.2M-$95.9M$28.3M-$92.2M-$170.5M
Net margin−4436.6%−3216.2%−1540.6%105.2%−646.0%−533.0%
Diluted EPS$-1.37$-0.47$-0.39$0.14$-0.47$-1.02
EBITDA-$103.4M-$90.2M-$82.3M-$63.8M-$77.6M-$68.0M
Operating cash flow-$87.8M-$68.2M-$66.9M-$65.0M-$55.8M-$77.0M
Free cash flow-$89.8M-$76.8M-$68.5M-$70.0M-$63.0M-$84.5M
Diluted shares313.0M267.7M244.5M200.4M197.8M167.1M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$30.2M$29.5M$7.6M$4.9M$36.4M$51.8M
Short-term investments$67.6M$68.4M$55.3M$51.1M$72.2M$48.3M
Total debt$93.2M$0.00$0.00$43.2M$179.9M$171.9M
Total assets$155.5M$145.3M$151.0M$216.0M$359.9M$314.6M
Total liabilities$134.6M$78.5M$32.5M$89.7M$252.5M$247.4M
Shareholders' equity$20.9M$38.5M$118.5M$126.3M$107.3M$67.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology